| abstract |
The present invention relates to novel uses of geldanamycin, dehydrocoastose lactone and / or rutacapine as inhibitors of the synthesis of prostaglandin E2. More specifically, lipopolysaccharide (LPS), a cell wall component of Gram-negative bacteria, using a geldanamycin compound, a dihydrocoastose lactone compound, and / or a rutacapine compound, which was not known as a conventional inhibitor of synthesis of prostaglandin E2. The present invention relates to a novel sepsis therapeutic agent that can be applied to the treatment of induced sepsis, such as sepsis. |